Lehigh Valley Health Network Selects StudyManager Reveal for Clinical Trial Management
StudyManager announced that Lehigh Valley Health Network selected StudyManager’s Reveal software to manage its clinical trials.
As a health network that includes three hospital facilities, nine health centers, and numerous primary and specialty care physician practices located throughout the state of Pennsylvania, Lehigh Valley Health Network sought a solution to centralize activity across multiple facilities and departments. Billing and protocol compliance, financial accountability, patient tracking, and high-level reporting for management oversight were all important criteria in selecting a CTMS system. Following an in-depth review process, Lehigh Valley selected StudyManager Reveal.
“We sought a CTMS that would centralize and organize our research operations to replace numerous manual and fragmented methods of capturing and recording data across our many research departments,” said Eric Mueller, MSA, Director of Research Administration, Lehigh Valley Health Network. “After evaluating several CTMS systems, we felt that StudyManager Reveal provided us the standardization needed, as well as the reporting capabilities to meet our compliance, study and patient tracking, and financial requirements.”
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
